ENTA - Enanta Pharmaceuticals Inc Stock Price, Fair Value and News

$6.28+0.42 (+7.17%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ENTA Price Action

Last 7 days

4.2%

Last 30 days

-30.8%

Last 90 days

-44.3%

Trailing 12 Months

-29.4%

ENTA RSI Chart

ENTA Valuation

Market Cap

133.1M

Price/Earnings (Trailing)

-1.15

Price/Sales (Trailing)

1.97

EV/EBITDA

-0.92

Price/Free Cashflow

-1.38

ENTA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ENTA Fundamentals

ENTA Revenue

Revenue (TTM)

67.6M

Rev. Growth (Yr)

-22.84%

Rev. Growth (Qtr)

-18.72%

ENTA Earnings

Earnings (TTM)

-116.0M

Earnings Growth (Yr)

-2.55%

Earnings Growth (Qtr)

-27.21%

ENTA Profitability

EBT Margin

-174.15%

Return on Equity

-90.09%

Return on Assets

-30.81%

Free Cashflow Yield

-72.66%

ENTA Investor Care

Shares Dilution (1Y)

0.64%

Diluted EPS (TTM)

-5.48

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	72.9M	72.0M	67.6M	0
2023	81.2M	80.6M	79.2M	73.6M
2022	91.6M	89.4M	86.2M	82.1M
2021	94.2M	97.1M	97.1M	93.0M
2020	175.9M	150.2M	122.5M	101.6M
2019	234.0M	221.1M	205.2M	187.9M
2018	165.6M	215.3M	206.6M	238.4M
2017	46.2M	39.7M	102.8M	130.5M
2016	87.5M	89.8M	88.3M	50.2M
2015	179.6M	149.1M	160.9M	131.8M
2014	6.1M	46.5M	47.7M	124.3M
2013	36.9M	34.5M	32.1M	5.1M
2012	0	0	41.7M	39.3M

Get all data in R, Python etc through our Historical Stock Data APIs

About Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

CEO	Dr. Jay R. Luly Ph.D.
WEBSITE	enanta.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	160

Enanta Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Enanta Pharmaceuticals Inc? What does ENTA stand for in stocks?

ENTA is the stock ticker symbol of Enanta Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Enanta Pharmaceuticals Inc (ENTA)?

As of Fri Dec 20 2024, market cap of Enanta Pharmaceuticals Inc is 133.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ENTA stock?

You can check ENTA's fair value in chart for subscribers.

Is Enanta Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ENTA is over valued or under valued. Whether Enanta Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Enanta Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ENTA.

What is Enanta Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, ENTA's PE ratio (Price to Earnings) is -1.15 and Price to Sales (PS) ratio is 1.97. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ENTA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Enanta Pharmaceuticals Inc's stock?

In the past 10 years, Enanta Pharmaceuticals Inc has provided -0.186 (multiply by 100 for percentage) rate of return.